Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns

Mar 24 2020

• By Mandy Jackson

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV — Lilly and Galapagos have paused certain trials due to coronavirus-related concerns

Related Content

Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says

Mar 19 2020

Accelerated Approval Submission On The HORIZON For Oncopeptides’ Melflufen

May 23 2019

Questions Persist On Lilly’s Tirzepatide And Tolerability

Jun 10 2019

Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

Oct 25 2019

Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

Jan 30 2020

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development

Mar 13 2020

Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out

Feb 05 2020

Follicum Details Clinical Progress Of Hair Growth Stimulating Product

Mar 29 2018

Syncona Biotechs Face Up To Trial Delays Over COVID-19

Mar 23 2020

Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist

Mar 19 2020

Related Companies

Eli Lilly and Company

Galapagos NV

AbCellera Biologics Inc.

Gilead Sciences, Inc.

Provention Bio, Inc.

Addex Therapeutics Ltd

Iveric Bio, Inc.

Oncopeptides AB

University of California, San Diego

University of California, San Diego

Additional Topics

Clinical Trials Coronavirus COVID-19 Business Strategies Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window